Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia
Pennsylvania
19104
United States
Website: http://www.amicusrx.com/
Email: info@amicusrx.com
About Amicus Therapeutics, Inc.
426 articles about Amicus Therapeutics, Inc.
-
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
2/8/2021
Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses Further Validates Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies to Develop Next Generation Gene Therapies
-
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
2/8/2021
Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease Plan to Submit IND for Next Clinical Study in 2H2021
-
Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021
1/21/2021
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that three oral presentations and ten posters highlighting its development programs for Lysosomal Disorders will be included at the 17th Annual WORLD Symposium ™ 2021 , to be held virtually February 8-12, 2021.
-
Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
Amicus Therapeutics announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference, being held virtually on Tuesday, January 12, 2021 at 8:20 a.m. ET.
-
Amicus Therapeutics Named a Great Place to Work-Certified™ Company in 2020
12/7/2020
Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced that it has been nationally recognized as a Great Place to Work-Certified™ Company in 2020.
-
Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors
12/2/2020
Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies. John F. Crowley, Chairman and Chief Executive Officer of A
-
Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease
12/1/2020
On Track for Completing the BLA Submission in 1H2021 All PPQ Drug Substance and Drug Product Activities for Man ufacturing Now Successfully Completed Data from Phase 3 Propel Study Expected 1Q2021
-
Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
11/23/2020
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference being held virtually on Tuesday, December 1, 2020 at 2:15 p.m. E.T.
-
Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
11/5/2020
Galafold 3Q20 Revenue of $67.4 Million, On-Track to Achieve Revenue Guidance of $250M-$260M AT-GAA Phase 3 PROPEL Study Readout in 1Q21 and Rolling BLA Submission to Begin in 4Q20 Positive CLN6 Batten Disease Gene Therapy Data Presented in October Fabry Disease Gene Therapy Clinical Candidate Selected Conference Call and Webcast Today at 8:30 a.m. ET
-
Amicus Therapeutics to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
11/2/2020
Amicus Therapeutics announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020 at 8:00 a.m. ET.
-
Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020
10/22/2020
Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2020.
-
Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society
10/12/2020
Data Continue to Support Meaningful Effect on Motor and Language Function in Children with Fatal Neurologic Disease
-
Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene TherapyAdditional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October
9/24/2020
Amicus Therapeutics announced the European Medicines Agency has granted Priority Medicines designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 disease, also known as CLN6 Batten disease.
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020
9/3/2020
Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September:
-
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
8/10/2020
Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of $250M-$260M AT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on Schedule Advancing Industry-Leading Rare Disease Gene Therapy Portfolio Path to Profitability Achieved without the Need for Any Future Dilutive Financings Conference Call and Webcast Today at 8:30 a.m. ET
-
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
8/4/2020
Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 9:00 a.m. E.T.
-
Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
7/28/2020
Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m.
-
Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing
7/17/2020
$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings Self-sustainable Financial Profile Achieved with Comprehensive, Low Cost Debt Structure and Includes Retiring Prior Term Loan Company Reiterates 2020 Galafold Revenue of $250-$260M and 2020 Operating Expense Guidance CRANBURY, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, develop
-
Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
6/4/2020
Amicus Therapeutics announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held virtually on Wednesday, June 10, 2020 at 8:00 a.m. ET.
-
Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders
5/8/2020
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that its 2020 Annual Meeting of Stockholders will now be held solely via live webcast due to the public health impact of the COVID-19 pandemic and out of an abundance of concern for the health and well-being of our employees, stockholders and directors. As p